High-dose melphalan plus bortezomib for multiple myeloma patients as a conditioning of auto-PBSCT

High-dose melphalan plus bortezomib for multiple myeloma patients as a conditioning of auto-PBSCT - FBMTG-MM10

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005582

Enrollment

Registered

2011-05-10

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

high-dose melphalan plus bortezomib as a conditioning of auto-PBSCT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients >SD 2)good PS 3)measurable disease 4)preserved organ function

Exclusion criteria

Exclusion criteria: 1)nonsecreatry MM or PCL 2)patinets underwent HSCT previously 3)> grade2 PN 4)HIV,HBV,HCV 5)patients suffering from other active cancers

Design outcomes

Primary

Measure	Time frame
To investigate the efficacy and safety of high-dose melphalan plus bortezomib for MM patients as a conditioning of auto-PBSCT.	—

Secondary

Measure	Time frame
1) ORR at day 100 2) PFS at 1-yr 3) OS at 1-yr	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026